Skip to main content
. 2022 Mar 14;28(6):1147–1156. doi: 10.1158/1078-0432.CCR-21-2023

Figure 1.

Figure 1. Forest plots of subgroup analyses of tislelizumab. A, Overall response rate. B, Complete response rate according to demographic and baseline disease characteristics. ASCT, autologous hematopoietic stem cell transplant; cHL, classical Hodgkin lymphoma; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate.

Forest plots of subgroup analyses of tislelizumab. A, Overall response rate. B, Complete response rate according to demographic and baseline disease characteristics. ASCT, autologous hematopoietic stem cell transplant; cHL, classical Hodgkin lymphoma; CI, confidence interval; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate.